The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OPK | -7.59% | -63.19% | -18.1% | -70% |
| S&P | +12.65% | +91.73% | +13.89% | +1,041% |
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
The FDA approved a growth therapy the company was collaborating on with Pfizer.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $151.67M | -12.6% |
| Gross Profit | $30.36M | 54.2% |
| Gross Margin | 20.02% | 8.7% |
| Market Cap | $1.23B | 18.4% |
| Market Cap / Employee | $0.41M | 0.0% |
| Employees | 3K | -23.7% |
| Net Income | $21.63M | -13.1% |
| EBITDA | -$30.78M | 63.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $415.20M | 2.2% |
| Accounts Receivable | $94.58M | -11.3% |
| Inventory | 65 | 9.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $371.07M | -23.4% |
| Short Term Debt | $24.35M | -13.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -8.49% | -2.3% |
| Return On Invested Capital | -6.45% | 2.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$37.78M | 55.6% |
| Operating Free Cash Flow | -$34.65M | 55.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.71 | 0.82 | 0.68 | 0.93 | 28.62% |
| Price to Sales | 1.96 | 1.62 | 1.57 | 1.88 | -9.95% |
| Price to Tangible Book Value | 32.20 | 45.35 | 12.40 | 19.58 | -40.02% |
| Enterprise Value to EBITDA | -162.42 | -26.76 | -31.50 | -38.63 | 101.49% |
| Return on Equity | -3.9% | -3.0% | -13.2% | -13.3% | 41.81% |
| Total Debt | $504.44M | $490.06M | $395.74M | $395.42M | -22.82% |
We said what? Let’s face it: Sometimes our predictions miss the mark, and with Rite Aid and Opko Health, they missed the mark by a lot. Here’s what we said, why we said it, and what we learned from our mistakes.
These been-there-done-that leaders are at the helm of four different emerging companies that investors should be paying attention to.
OPK earnings call for the period ending December 31, 2024.
OPK earnings call for the period ending September 30, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
